

OCT. 27. 2004 10:11AM

GW GLOBAL R&D IS

NO. 8710 P. 1

RECEIVED
CENTRAL FAX CENTER

OCT 27 2004



GlaxoSmithKline

FAX

To Art Unit 1626, Examiner G. Shameem
Company USPTO
Fax 703-872-9306
From Valerie L. Phillips
Tel 919-483-8223 Fax 919-483-5730
E-mail Vlp47157@gsk.com
Date October 27, 2004 Pages including cover
Subject Response to Office Action


Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/019,976
Date: October 23, 2001
Applicant: Bingham et al.
Title: Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands


Attached:
Response to Office Action
Amendment Transmittal Letter
Certificate of Transmission By Facsimile

Thank you,
Valerie Phillips

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax, No. 703-872-9306) on October 27, 2004.


Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PU3650USW	
Applicant(s): Bingham et al.					
Serial No. 10/019,976	Filing Date October 23, 2001	Examiner G. Shameem	Group Art Unit 1626		
Invention: Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	-	20 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	-	3 =	0 x	\$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 _____ Signature Robert H. Brink, Reg. No. 36,094			Dated: <i>27 October 2004</i>		
CC:			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37C.F.R. 1.8 and is addressed to the for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. _____ Signature of Person Mailing Correspondence _____ Typed or Printed Name of Person Mailing Correspondence		

P11LARGE/REV08

OCT. 27. 2004 10:11AM

GW GLOBAL R&D IS

NO. 8710 P. 3

PU3650-USW

RECEIVED
CENTRAL FAX CENTER

OCT 27 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bigham, et al.

Filed: October 23, 2001

Art Unit: 1626

Serial No.: 10/019,976

Examiner: G. Shameem

For: Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands

Assistant Commissioner of Patents

Washington, DC. 20231

Response

This is in response to the Office Action mailed October 1, 2004.